Some recent studies have shown that the effect of TNF blockage also appears to be impaired in obese RA patients, while no significant difference between obese and non-obese were seen in patients treated with abatacept and tocilizumab (Klaasen et al., 2011; Gremese et al., 2013; Iannone et al., 2015; Kim et al., 2016; Shan and Zhang, 2018). Here, TNF is linked to rheumatoid arthritis.